EMEA Suspends Hexavac Marketing Authorization
This article was originally published in The Pink Sheet Daily
Executive Summary
Decreased immunogenicity of Sanofi-Pasteur/Merck’s hepatitis B component appears to have been caused by “variability in the production process.”